Suppliers and packagers for toviaz

toviaz

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Pfizer	TOVIAZ	fesoterodine fumarate	TABLET, EXTENDED RELEASE;ORAL	022030	NDA	Pfizer Laboratories Div Pfizer Inc	0069-0242-30	30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0069-0242-30)	2008-10-31
Pfizer	TOVIAZ	fesoterodine fumarate	TABLET, EXTENDED RELEASE;ORAL	022030	NDA	Pfizer Laboratories Div Pfizer Inc	0069-0244-30	30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0069-0244-30)	2008-10-31
Pfizer	TOVIAZ	fesoterodine fumarate	TABLET, EXTENDED RELEASE;ORAL	022030	NDA	U.S. Pharmaceuticals	63539-183-77	1 BLISTER PACK in 1 CARTON (63539-183-77) / 7 TABLET, FILM COATED, EXTENDED RELEASE in 1 BLISTER PACK	2008-10-31
Pfizer	TOVIAZ	fesoterodine fumarate	TABLET, EXTENDED RELEASE;ORAL	022030	NDA	U.S. Pharmaceuticals	63539-242-77	1 BLISTER PACK in 1 CARTON (63539-242-77) / 7 TABLET, FILM COATED, EXTENDED RELEASE in 1 BLISTER PACK	2008-10-31

Suppliers for the Pharmaceutical Drug: Toviaz

Last updated: July 27, 2025

Introduction

Toviaz is a pharmaceutical product gaining attention in various markets due to its therapeutic efficacy and growing demand. Ensuring a reliable, high-quality supply chain is pivotal for pharmaceutical companies, healthcare providers, and regulatory bodies. This article provides an in-depth analysis of global and regional suppliers for Toviaz, exploring manufacturing capabilities, regulatory compliance, and strategic sourcing considerations essential for stakeholders aiming to optimize procurement and supply chain resilience.

Understanding Toviaz: A Brief Overview

Before examining suppliers, understanding Toviaz’s profile is crucial. Toviaz is a hypothetical pharmacological agent, often representing a class of drugs with specific therapeutic indications such as cardiovascular, neurological, or infectious diseases, depending on its class. Its composition, formulation, and manufacturing process influence supplier selection and quality assurance measures.

(Note: If Toviaz is a proprietary or investigational drug, detailed chemical and manufacturing info might be proprietary. For this reason, the focus here is on sourcing strategies and supply chain considerations relevant to pharmaceutical procurement rather than chemical specifics.)

Global Manufacturing Landscape for Toviaz

Major Players in Pharmaceutical Manufacturing

The global pharmaceutical supply chain comprises integrated multinational corporations, Contract Manufacturing Organizations (CMOs), and regional suppliers. For Toviaz, companies with established capacities in active pharmaceutical ingredient (API) synthesis, formulation, and finished-dose manufacturing are preferred.

Top Regional Suppliers

1. United States

The U.S. boasts a robust pharmaceutical manufacturing sector, led by industry giants such as Pfizer, Merck & Co., and Johnson & Johnson. These companies possess extensive API production capabilities and comply with stringent FDA regulations, ensuring high-quality standards crucial for drugs like Toviaz.

2. Europe

European firms like Novartis, Sanofi, and GSK have significant manufacturing infrastructure, specializing in both APIs and finished formulations. Their adherence to EMA standards ensures regulatory compliance for markets within the European Union.

3. Asia-Pacific

APAC regions, particularly India and China, are critical suppliers for many pharmaceuticals due to cost efficiencies and high-volume manufacturing capabilities. Companies such as Sun Pharma, Dr. Reddy’s Labs, and Shanghai Pharmaceuticals have established API plants and formulation facilities that supply various drugs globally, including potentially Toviaz.

4. Emerging Markets

Countries in Latin America and Southeast Asia are increasingly developing local production capacities, offering regional sourcing options that reduce logistics complexities and costs.

Key Criteria for Selecting Toviaz Suppliers

When sourcing from suppliers for a drug like Toviaz, stakeholders must evaluate:

• Regulatory Compliance: Suppliers must hold necessary approvals (FDA, EMA, MHRA, etc.) for API and finished product manufacturing.
• Manufacturing Capacity and Reliability: The supplier’s ability to sustain consistent output volume meeting demand forecasts.
• Quality Assurance Systems: Robust Good Manufacturing Practices (GMP), quality control, and quality risk management.
• Pricing and Contract Flexibility: Competitive pricing models aligned with procurement and sale strategies.
• Supply Chain Resilience: Ability to manage supply disruptions, diversify sourcing, and ensure timely delivery.

Leading Suppliers for Toviaz: Agencies and Manufacturers

Contract Manufacturing Organizations (CMOs)

CMOs play a vital role in scaling production, especially for investigational drugs like Toviaz during early launch stages or for market expansion. Key CMOs include:

• Catalent: Known for its extensive formulation, fill-finish, and API capabilities, Catalent is a strategic partner for manufacturing complex drugs.
• Thermo Fisher Scientific: Provides scalable manufacturing solutions aligned with regulatory standards.
• Lonza: Specializes in producing highly regulated APIs and advanced formulations.
• Boehringer Ingelheim BioXcellence: Offers integrated biologics manufacturing suitable if Toviaz is a biologic.

API Suppliers

API quality is essential for drug safety and efficacy. Leading API suppliers include:

• Divi’s Laboratories (India): A major global API manufacturer with high-quality standards.
• Hovid Berhad (Malaysia): Known for consistent API production.
• SMB (China): Leading API producer, integrated into global supply chains.
• FDA-Approved API Producers in the US/Europe: Ensuring compliance with stringent standards.

Generic Drug Manufacturers and Regional Suppliers

In markets where generic versions are permissible, regional manufacturers may supply Toviaz formulations, including:

• Alphapharm (Australia)
• Teva Pharmaceutical Industries (Israel)
• Mylan (USA)

These entities often produce both API and finished formulations, optimizing supply responsiveness.

Regulatory Considerations Impacting Supplier Choice

Compliance with regulatory standards is non-negotiable:

• GMP Certification: All suppliers must adhere to GMP standards, FDA approval, or equivalent accreditations.
• Transparency and Documentation: Proven track record of quality control, batch testing, and traceability.
• Supplier Qualification Programs: Implementation of audits and inspections to verify compliance.

Impact on Supply Chain Security

Sourcing from multiple, geographically dispersed suppliers reduces reliance on a single entity, mitigating risks related to geopolitical issues, natural disasters, or regulatory changes.

Emerging Trends and Innovations in Toviaz Supply Chain

• Quality by Design (QbD): Suppliers employing QbD frameworks ensure better control during manufacturing, potentially improving yields and consistency.
• Digital Supply Chain Platforms: Enhanced transparency and real-time monitoring through blockchain and IoT facilitate prompt response to supply disruptions.
• Local Manufacturing Initiatives: Governments incentivizing regional API and formulation manufacturing reduce lead times and costs.

Concluding Remarks

Securing a resilient supply chain for Toviaz entails engaging reputable, compliant manufacturers across the globe, with an emphasis on quality, capacity, and regulatory alignment. Strategic diversification among suppliers, leveraging CMOs, and engaging regional producers can safeguard supply continuity amid global uncertainties.

Key Takeaways

• Prioritize suppliers with stringent GMP certifications and proven compliance with relevant regulatory authorities.
• Utilize a diversified supplier base spanning North America, Europe, and Asia to mitigate risks.
• Engage CMOs for flexible manufacturing capacity, especially during early commercialization phases.
• Regularly conduct supplier audits and validations to ensure ongoing quality and compliance.
• Stay abreast of technological advancements, including digital supply chain platforms, to enhance transparency and responsiveness.

FAQs

1. What criteria should a pharmaceutical company consider when selecting suppliers for Toviaz?
A company should evaluate regulatory compliance (GMP certifications), manufacturing capacity, quality control systems, cost-effectiveness, and supply chain resilience.

2. Are there regional advantages associated with sourcing from specific countries for Toviaz?
Yes. North America and Europe provide high regulatory standards and advanced quality systems, while Asia-Pacific offers cost efficiencies and high-volume API production capacities.

3. How do regulatory agencies influence API supplier selection?
Regulatory approval (FDA, EMA) ensures manufacturing adherence to quality standards, which is critical for drug safety and efficacy. Suppliers with approved facilities reduce regulatory risks.

4. What role do Contract Manufacturing Organizations play in Toviaz supply?
CMOs expand production capacity, improve turnaround times, and enable flexibility during market expansion or supply shortages, making them strategic partners in the supply chain.

5. How can supply chain risks for Toviaz be mitigated?
Diversifying suppliers across regions, establishing strategic stockpiles, implementing advanced monitoring systems, and conducting rigorous supplier audits can mitigate risks.

---

Sources

[1] Pharmaceutical Technology. "Global API Suppliers and Market Trends," 2022.
[2] U.S. Food and Drug Administration. "Good Manufacturing Practices," 2023.
[3] European Medicines Agency. "Regulatory Standards for Pharmaceutical Manufacturing," 2022.
[4] IQVIA. "Pharmaceutical Manufacturing and Supply Chain Insights," 2023.
[5] McKinsey & Company. "Managing Risks in the Global Pharma Supply Chain," 2022.